Show simple item record

dc.contributor.authorDurmuş, Ali
dc.contributor.authorYılmaz, Ahmet
dc.contributor.authorMalya, Fatma Ümit
dc.contributor.authorÖztürk, Gökmen
dc.contributor.authorBektaşoǧlu, Hüseyin Kazım
dc.contributor.authorErtuğrul, G.
dc.contributor.authorKaryağar Sağlampınar, Sevda
dc.contributor.authorKaratepe, Oǧuzhan
dc.date.accessioned2020-08-12T09:11:14Z
dc.date.available2020-08-12T09:11:14Z
dc.date.issued2016en_US
dc.identifier.citationDurmuş, A., Yılmaz, A., Malya, F. Ü., Öztürk, G., Bektaşoǧlu, H. K., Ertuğrul, G. ... Karatepe, O. (2016). The use of 18f-fluorodeoxyglucose positron emission tomography to assess clinical outcomes of patients wıth borderline resectable pancreatic cancer, 253, 26-29.en_US
dc.identifier.issn1512-0112
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5698
dc.description.abstractThe aim of this study is to evaluate the effect of 18FDG PET on preoperative staging and clinical management of pancreatic cancer. Between December 2011 and February 2015, 28 consecutive patients with borderline resectable pancreatic cancer were evaluated with both 18FDG PET scans and conventional preoperative imaging studies. Medical records of all patients were noted prospectively. 18FDG PET findings were compared with conventional imaging studies and over-staging or down-staging rates with changes in clinical management were evaluated. The correlation of 18FDG PET with conventional imaging studies was evaluated with a kappa agreement coefficient. A number of 22 (78.5%) patients had pancreatic head cancer and 6 (21.4%) patients had pancreatic body and tail cancers. Based on 18FDG PET, additional lesions were found in 4 (14.28%) of the patients which were lung and peritoneal lesions as metastasis. No hepatic metastasis or supraclavicular lymph node involvement was confirmed in patients. Routine use of 18FDG PET for preoperative staging has not an effect on cancer management in 96.8% of our patients. In conclusion, 18FDG PET has additional value over conventional radiologic techniques for monitoring the treatment response in locally advanced pancreatic cancer patients. It is feasible to predict early metastasis and patient outcome early (after one course of IC) during therapy.en_US
dc.language.isoengen_US
dc.publisherGeorgian Association of Business Pressen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFluorodeoxyglucoseen_US
dc.subjectTomographyen_US
dc.subjectPancreatic Canceren_US
dc.titleThe use of 18f-fluorodeoxyglucose positron emission tomography to assess clinical outcomes of patients wıth borderline resectable pancreatic canceren_US
dc.typearticleen_US
dc.relation.ispartofGeorgian Medical Newsen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Genel Cerrahi Ana Bilim Dalıen_US
dc.identifier.issue253en_US
dc.identifier.startpage26en_US
dc.identifier.endpage29en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.scopusqualityQ4en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record